[Met]enkephalin   Click here for help

GtoPdb Ligand ID: 1614

Synonyms: 1-5 Adrenorphin | [Met]-enkephalin | IRT-101 | methionine enkephalin | np2 enkephalin | opioid growth factor (OGF)
Immunopharmacology Ligand
Comment: MET-enkephalin (MENK) is an endogenous opioid peptide. It exhibits agonist activity at the δ- and μ-opioid receptors. MENK produces immunomodulatory, neuromodulatory, antinociceptive/analgesic, antidepressant, and gastrointestinal motility modulating activities. It has cytostatic activity vs. cancer cells and may help recruit NK cells to kill tumour cells [3,5,8].
Species: Human, Mouse, Rat
Click here for help
2D Structure
Click here for help
Click here for structure editor
Click here for help
Canonical SMILES CSCCC(C(=O)O)NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)C(Cc1ccc(cc1)O)N
Isomeric SMILES CSCC[C@@H](C(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(cc1)O)N
InChI InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)/t20-,21-,22-/m0/s1
No information available.
Summary of Clinical Use Click here for help
The immuno-regulating effects of MENK have been investigated for clinical utility in MS patients, and it has been trialled in cancer patients. EK-12 (Enkorten) is a combination of MENK + tridecactide (alpha-corticotropin 1-13, a.k.a. (Des-acetyl)-α-MSH), that is proposed as a potent immunomodulatory therapy. This is in active clinical trial for relapsing-remitting MS.

SARS-CoV-2 infection (COVID-19): EK-12 has also entered clinical trial in COVID-19 patients with moderate-severe disease in Bosnia.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04374032 Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection Phase 2/Phase 3 Interventional Bosnalijek D.D
NCT03283397 A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS Phase 3 Interventional Bosnalijek D.D